Biodesix (BDSX) Research & Development (2019 - 2026)

Biodesix has reported Research & Development for 8 years, with the latest figure at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 14.46% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (up 19.51% YoY), and the FY2025 full-year result was $12.0 million, up 25.55% from the prior year.
• Research & Development for Q1 2026 stood at $3.3 million, up from $2.9 million in the prior quarter.
• The five-year high for Research & Development was $3.6 million in Q4 2022, with the low at $1.9 million in Q4 2023.
• Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development plunged 47.01% — and 2025, when it jumped 40.69%.
• Biodesix's Research & Development stood at $3.6 million in 2022, then tumbled by 47.01% to $1.9 million in 2023, then climbed by 27.79% to $2.4 million in 2024, then gained by 18.89% to $2.9 million in 2025, then climbed by 14.46% to $3.3 million in 2026.
• The last three Research & Development figures came in at $3.3 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.